CureOne has partnered with the Washington University School of Medicine in St. Louis to consolidate and standardize genomic cancer data. Under the terms of the agreement, CureOne will work with the university’s clinical next-generation sequencing (NGS) laboratory, Genomics and Pathology Services (GPS), to achieve this goal through the N1 Registry. CureOne created the N1 Registry to serve as an open-access database that links NGS data with information about molecular or immunological testing and treatments, as well as clinical outcomes data. The N1 Registry also acts as a conduit for enrollment in clinical trials and collects information on the growing number of patients who receive NGS testing.
Washington University School of Medicine is the first academic organization to collaborate with CureOne, and CureOne plans to leverage the university’s extensive experience helping other laboratories and regulatory partners to understand and build clinical NGS tests for cancer. “In collaboration with CureOne, we’ll provide high-quality, mutational profiles for patients enrolled in [the N1 Registry], hopefully across many different cancer types,” said Jon Heusel, MD, PhD, chief medical officer at GPS. “As the N1 Registry grows, we expect it will include many thousands of cases [including rare cancers] where the genomic data, patient phenotypic data, and clinical outcomes data are all aligned and high-quality … which are essential to drawing significant conclusions that can inform precision cancer treatments.”